US Stock MarketDetailed Quotes

CELUW CELULARITY INC C/WTS 24/05/2026 (TO PUR COM)

Watchlist
  • 0.0350
  • 0.00000.00%
Close Apr 23 16:00 ET
0Market Cap0.00P/E (TTM)

About CELULARITY INC C/WTS 24/05/2026 (TO PUR COM) Company

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Company Profile

SymbolCELUW
Company NameCELULARITY INC C/WTS 24/05/2026 (TO PUR COM)
Listing DateAug 8, 2019
Founded2016
CEODr. Robert J. Hariri, M.D.,PhD
MarketNASDAQ
Employees225
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address170 Park Avenue
CityFlorham Park
ProvinceNew Jersey
CountryUnited States of America
Zip Code07932
Phone1-908-768-2170

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Robert J. Hariri, M.D.,PhD
  • Chief Executive Officer and Chairman of the Board
  • 5.24M
  • David C. Beers
  • Chief Financial Officer and Principal Accounting Officer
  • 1.71M
  • Dr. Adrian Kilcoyne, M.D.
  • Executive Vice President and Chief Medical Officer
  • --
  • John R. Haines
  • Senior Executive Vice President, General Manager and Chief Administrative Officer
  • 2.50M
  • Keary L. Dunn, Esq.
  • Executive Vice President, Chief Legal Officer, General Counsel and Business Development
  • --
  • K. Harold Fletcher
  • Executive Vice President and General Counsel
  • --
  • Stephen A. Brigido, D.P.M.
  • President, Degenerative Disease
  • --
  • Dr. Geoffrey Shiu Fei Ling
  • Director
  • --
  • Dean C. Kehler
  • Independent Director
  • 373.00K
  • Marc Mazur
  • Independent Director
  • 371.00K
  • Dr. Peter H. Diamandis, M.D.
  • Independent Director
  • 353.50K
  • Diane L. Parks, M.B.A.
  • Independent Director
  • 627.68K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg